SearchProgram details
Diagnosis and Treatment of Early-Stage Alzheimer's Disease【National Cerebral and Cardiovascular Center】
No.
Internal medicineNeurology
National Cerebral and Cardiovascular Center (NCVC)（Kinki/Osaka）
We conduct a comprehensive evaluation of the eligibility for anti-amyloid beta monoclonal antibody therapy in patients with early-stage Alzheimer's disease and provide short-term inpatient care.
Anti-amyloid beta monoclonal antibody therapy has been approved for early-stage Alzheimer's disease. At our hospital, we offer short-term inpatient evaluation to comprehensively assess patient eligibility for this treatment. Approximately 100 patients are admitted annually for detailed assessment, and about 60% of them subsequently receive outpatient anti-amyloid beta antibody therapy.
- Genres
-
- Department Internal medicine
- Disease
- Examination Items/Treatments/Surgical method
- Region/Organ
- Program Summary
- During a standard 3-day, 2-night hospitalization, we perform a comprehensive cognitive function assessment, evaluate the risk of side effects from anti-amyloid beta antibodies, quantify amyloid beta accumulation in the brain, and measure cerebral blood flow, which affects cognitive function. Based on these results, dementia specialists assess the efficacy and safety of anti-amyloid beta therapy.
If early-stage Alzheimer's disease is confirmed and the patient is deemed eligible for treatment, a 2-day, 1-night hospital stay is arranged for the first infusion to monitor for any side effects until the following day.
We take every possible measure to ensure the treatment is provided safely and with the utmost care.
- Medical Institutions
-
National Cerebral and Cardiovascular Center (NCVC)
〒564-8565
6-1 Kishibeshinmachi, Suita,
Google Map
- Examination Items
- Setup Date
- Excluded days
- Eligibility Criteria/Exclusions for Treatment
- Individuals who are aware of memory loss or have been noticed by others to have memory difficulties are eligible for a 3-day, 2-night inpatient evaluation. Anti-amyloid beta antibody therapy is administered in the hospital for the first dose only. From the second dose onward, treatment is typically continued on an outpatient basis every 2 or 4 weeks for a period of 1 to 1.5 years. Each treatment session takes approximately 30 to 60 minutes.
- Precautions / Contraindications
- This program is intended for individuals with early-stage Alzheimer's disease. Those with advanced cognitive decline may not be eligible. We strongly recommend seeking medical evaluation as early as possible if you notice symptoms of memory loss.
